Program
Trijardy® XR Tablets
Also written as “Trijardy® XR Extended release film coated tablets”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Humanis Saglık Anonim Sirketi.
Furthest: phase 1, since Oct 2, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Humanis Saglık Anonim Sirketi | 30 open or running | phase 1since Oct 2, 2025 | Oct 2, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 2, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07213895 · 14 enrolled · Jordan
- Jul 1, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07691203 · 36 enrolled · India
- Oct 7, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07872358 · 36 enrolled · India
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07872358Diabetes Mellitus, Type 2 · India | 1 | Completed | Jul 30, 2026 | 36 |
| NCT07691203Diabetes Mellitus, Type 2 · India | 1 | Completed | Jun 16, 2026 | 36 |
| NCT07213895Diabetes Mellitus, Type 2 · Jordan | 1 | Completed | Sep 15, 2025 | 14 |
How it is read
Names in the registry
- “Trijardy® XR Tablets”, 2 entries
- “Trijardy® XR Extended release film coated tablets”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.